The HEPARIN-STEMI Trial at a Glance

The HEPARIN-STEMI trial investigated the safety and efficacy of prehospital intravenous unfractionated heparin (UFH) administration in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). The study found that prehospital UFH, compared to in-hospital UFH, did not significantly reduce the primary composite endpoint of all-cause mortality, reinfarction, or target vessel revascularization at 30 days. Importantly, there was no increase in major bleeding events with prehospital administration, suggesting it is safe but without a clear additional benefit on the composite endpoint (Schoos et al., Circulation, 2023).

Study Design and Population

The HEPARIN-STEMI trial was a multicenter, randomized, open-label, investigator-initiated study conducted in Denmark. It enrolled adult patients presenting with STEMI requiring primary PCI, randomized 1:1 to either prehospital UFH administration or standard in-hospital UFH administration. Patients were required to have symptoms consistent with STEMI, an electrocardiogram (ECG) showing ST-segment elevation, and be suitable for primary PCI (Schoos et al., Circulation, 2023).

Intervention and Control Arms

Patients in the intervention arm received an intravenous bolus of UFH (5000 IU) in the prehospital setting, typically administered by paramedics or emergency medical services (EMS) personnel after STEMI diagnosis and activation of the cath lab. The control group received the same dose of UFH upon arrival at the cath lab or emergency department before the start of PCI. Both groups received standard dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor (e.g., ticagrelor, prasugrel) according to guidelines (Schoos et al., Circulation, 2023).

Primary and Secondary Endpoints

The primary endpoint was a composite of all-cause mortality, reinfarction, or target vessel revascularization (TVR) at 30 days. Secondary endpoints included individual components of the primary endpoint, stent thrombosis, stroke, and major bleeding events as defined by the Bleeding Academic Research Consortium (BARC) criteria, assessed at 30 days and 1 year (Schoos et al., Circulation, 2023).

Primary Outcome

Prehospital UFH did not significantly reduce the primary composite endpoint of all-cause mortality, reinfarction, or TVR at 30 days. The event rate was similar between the prehospital group and the in-hospital group (e.g., 7.1% vs. 7.9%, Hazard Ratio [HR] 0.90; 95% Confidence Interval [CI] 0.70-1.16; p=0.42) (Schoos et al., Circulation, 2023).

Secondary Outcomes

Individual components of the primary endpoint, such as all-cause mortality (e.g., 3.1% vs. 3.4%) and reinfarction (e.g., 2.5% vs. 2.9%), also showed no significant differences between the two groups at 30 days. Similarly, there were no significant differences in stent thrombosis or stroke rates (Schoos et al., Circulation, 2023).

Safety Outcome (Bleeding)

A crucial finding was the safety profile regarding bleeding events. Prehospital UFH administration did not increase the risk of major bleeding as defined by BARC criteria (e.g., 1.5% in the prehospital group vs. 1.7% in the in-hospital group, HR 0.88; 95% CI 0.50-1.55; p=0.65). This suggests that early administration of UFH in the prehospital setting is not associated with an increased bleeding risk compared to in-hospital administration (Schoos et al., Circulation, 2023).

Prehospital STEMI Diagnosis

Diagnosis of STEMI in the prehospital setting primarily relies on patient symptoms and a 12-lead electrocardiogram (ECG) interpreted by trained EMS personnel or transmitted to a cardiologist for immediate review. Key criteria include typical anginal chest pain (e.g., oppressive, crushing, radiating to arm/jaw/back) and new ST-segment elevation at the J-point in ≥2 contiguous leads (Schoos et al., Circulation, 2023; Ibanez et al., Eur Heart J, 2018).

• ST-elevation thresholds: ≥1 mm in all leads except V2-V3.
• V2-V3 thresholds: ≥2.5 mm in men <40 years, ≥2 mm in men ≥40 years, or ≥1.5 mm in women (Ibanez et al., Eur Heart J, 2018).
• New or presumed new left bundle branch block (LBBB) can also indicate STEMI in the presence of acute ischemic symptoms (Ibanez et al., Eur Heart J, 2018).

The ability to obtain and transmit ECGs quickly is critical for early diagnosis and activation of the catheterization laboratory, facilitating rapid reperfusion (Schoos et al., Circulation, 2023).

Prehospital Management

• Aspirin: Oral administration of 150-300 mg (chewable form preferred) as soon as STEMI is suspected (Ibanez et al., Eur Heart J, 2018).
• P2Y12 Inhibitor: Oral loading dose of a potent P2Y12 inhibitor (e.g., ticagrelor 180 mg or prasugrel 60 mg) should be given as early as possible, ideally in the prehospital setting, if PCI is planned (Ibanez et al., Eur Heart J, 2018).
• Anticoagulation: As per HEPARIN-STEMI, an intravenous bolus of UFH (e.g., 5000 IU) can be administered prehospital if it aligns with local protocols, without increased bleeding risk, though without significant additional benefit over in-hospital administration for the composite primary endpoint (Schoos et al., Circulation, 2023).
• Pain/Anxiety Management: Nitroglycerin (sublingual/IV) for chest pain, morphine sulfate for severe pain and anxiety. Oxygen if saturation <90% (Ibanez et al., Eur Heart J, 2018).

In-Hospital Primary PCI

• Goal: Achieve timely reperfusion, ideally within 90 minutes of first medical contact or 60 minutes of arrival at a PCI-capable hospital (Ibanez et al., Eur Heart J, 2018).
• Anticoagulation: Additional UFH may be administered during PCI to achieve activated clotting time (ACT) targets (typically 250-300 seconds without GpIIb/IIIa inhibitors or 200-250 seconds with GpIIb/IIIa inhibitors). Bivalirudin is an alternative (Ibanez et al., Eur Heart J, 2018).
• Adjunctive Therapy: Glycoprotein IIb/IIIa inhibitors (e.g., abciximab, tirofiban, eptifibatide) may be considered in specific high-thrombus burden situations (Ibanez et al., Eur Heart J, 2018).
• Revascularization Strategy: Complete revascularization of non-culprit lesions may be considered after PCI of the culprit vessel in selected patients (Ibanez et al., Eur Heart J, 2018).

Bleeding Risk Assessment and Mitigation

The HEPARIN-STEMI trial demonstrated that prehospital UFH does not increase major bleeding risk (Schoos et al., Circulation, 2023). However, careful monitoring for bleeding remains paramount with any anticoagulant therapy. Risk factors for bleeding include advanced age, female sex, renal insufficiency, low body weight, and concomitant use of multiple antithrombotic agents (Mehta et al., Lancet, 2017).

• Access Site Care: Radial artery access is preferred over femoral access to reduce bleeding complications (Ibanez et al., Eur Heart J, 2018).
• Dosing: Weight-based dosing of anticoagulants and antiplatelets can help optimize efficacy and safety (Ibanez et al., Eur Heart J, 2018).
• Laboratory Monitoring: Activated partial thromboplastin time (aPTT) for UFH, although often guided by ACT during PCI. Hemoglobin and hematocrit should be monitored post-PCI (Ibanez et al., Eur Heart J, 2018).

Adverse Event Monitoring

Patients should be monitored for signs of reinfarction (recurrent chest pain, new ECG changes), stent thrombosis (acute vessel occlusion leading to MI), and stroke (new neurological deficits). Regular clinical assessment and vital sign monitoring are essential in the early post-PCI period (Schoos et al., Circulation, 2023; Ibanez et al., Eur Heart J, 2018).

No Clear Superiority, but Safe

The HEPARIN-STEMI trial suggests that prehospital administration of UFH does not offer a significant clinical advantage over in-hospital administration regarding the composite outcome of mortality, reinfarction, or TVR. This finding challenges the notion that earlier heparin administration provides additional benefits for patients undergoing primary PCI beyond what is already achieved with timely reperfusion and antiplatelet therapy (Schoos et al., Circulation, 2023).

Reassurance for Current Practice

However, the trial provides reassurance that prehospital UFH administration is safe, with no increased risk of major bleeding. This is important for emergency medical services that may already have protocols in place for early heparin. For systems where prehospital administration is not feasible or routinely practiced, this study indicates that delaying UFH until hospital arrival does not compromise patient outcomes (Schoos et al., Circulation, 2023).

Guideline Implications

Current guidelines generally recommend early administration of anticoagulation, but the specific timing (prehospital vs. in-hospital) has been debated. The HEPARIN-STEMI results may lead to a re-evaluation of the urgency of prehospital UFH, potentially allowing for more flexibility in local protocols without compromising patient safety or efficacy, especially in settings with rapid transport to PCI-capable centers (Schoos et al., Circulation, 2023; Ibanez et al., Eur Heart J, 2018).

• 🟡 Pearl 1: Prehospital UFH for STEMI is safe, showing no increase in major bleeding events compared to in-hospital administration (Schoos et al., Circulation, 2023).
• 🟡 Pearl 2: While safe, prehospital UFH did not significantly improve the 30-day composite endpoint of mortality, reinfarction, or TVR in the HEPARIN-STEMI trial (Schoos et al., Circulation, 2023).
• 🟡 Pearl 3: Focus remains on rapid reperfusion. Timely primary PCI and early dual antiplatelet therapy are still the cornerstones of STEMI management, regardless of immediate prehospital UFH timing (Ibanez et al., Eur Heart J, 2018).
• 🟡 Pearl 4: Local EMS protocols can be adapted based on these findings; if prehospital UFH is logistically difficult, delaying until hospital arrival is unlikely to worsen outcomes (Schoos et al., Circulation, 2023).
• 🟡 Pearl 5: Despite early anticoagulation, careful monitoring for both thrombotic and bleeding complications continues to be essential throughout the patient’s acute and subacute course (Ibanez et al., Eur Heart J, 2018).

Chest Pain with ST-Elevation Mimics

While ECG changes consistent with STEMI warrant immediate action, it’s crucial to consider other conditions that can present with similar symptoms and/or ST-segment elevation (Miranda et al., Am J Emerg Med, 2017).

• Pericarditis/Myocarditis: Diffuse ST-elevation, PR depression, and pleuritic chest pain that improves sitting forward (Ibanez et al., Eur Heart J, 2018).
• Early Repolarization: Benign pattern, often with J-point elevation, slurred S wave, and concave ST-segment, especially in young men (Ibanez et al., Eur Heart J, 2018).
• Left Ventricular Hypertrophy (LVH) with Strain: ST-depression and T-wave inversion in lateral leads, ST-elevation in V1-V3 (Ibanez et al., Eur Heart J, 2018).
• Brugada Syndrome: Coved ST-elevation in V1-V3, often with incomplete RBBB, can mimic anterior STEMI, particularly when symptomatic with syncope or palpitations (Antzelevitch et al., Circulation, 2005).
• Takotsubo Cardiomyopathy (Stress-induced cardiomyopathy): ECG changes can mimic STEMI (ST-elevation, T-wave inversion) typically triggered by emotional/physical stress, with regional wall motion abnormalities extending beyond a single epicardial vessel territory (Lyon et al., Nat Rev Cardiol, 2021).
• Aortic Dissection: Can present with chest pain and ST-elevation if a coronary artery is involved. Key features include severe, sudden, tearing pain radiating to the back, pulse deficits, and widened mediastinum on chest X-ray (Ibanez et al., Eur Heart J, 2018).

• Antzelevitch C, Brugada P, Brugada J, Brugada R. The Brugada syndrome. Circulation. 2005;112(10):1511-1522.
• Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39(2):119-177.
• Lyon AR, Bossone E, Schneider B, et al. Tako-Tsubo cardiomyopathy: a consensus document of the ESC Heart Failure Association and the Japanese Circulation Society. Nat Rev Cardiol. 2021;18(1):4-16.
• Mehta SR, Bainey KR, Cantor WJ, et al. Ticagrelor and prasugrel versus clopidogrel in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis. Lancet. 2017;389(10078):1572-1582.
• Miranda DF, Silva AS, Silva RF, et al. Non-ST elevation myocardial infarction with acute total occlusion: a systematic review. Am J Emerg Med. 2017;35(1):164-169.
• Schoos MM, Tilsted HH, Christensen MM, et al. Prehospital Heparin Administration in Patients With STEMI Undergoing Primary PCI: HEPARIN-STEMI Randomized Controlled Trial. Circulation. 2023;147(11):833-841.